Is Senores Pharmaceuticals the Best Stock in Its Sector? A Look at the Numbers

Senores Pharmaceuticals CMP Rs 1,401 (07 Oct 2026). Market cap Rs 6,389 Cr. ROE 12.36%. P/E 48.83x versus Industry P/E 37.19x.

Is Senores Pharmaceuticals the best stock in its sector? The stock trades on the NSE at Rs 1,401 as of 07 October 2026, within its 52-week range of Rs 700.75 to Rs 1,599.00. Senores Pharmaceuticals Ltd, based in Ahmedabad, develops and sells generic pharmaceutical formulations, mainly for regulated markets such as the US.

Senores Pharmaceuticals sits in the Pharmaceuticals sector, and its 12.36% ROE and 48.83x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Senores Pharmaceuticals

Senores Pharmaceuticals Ltd, based in Ahmedabad, develops and sells generic pharmaceutical formulations, mainly for regulated markets such as the US. The stock is trading about 12 percent below its 52-week high after doubling from its 52-week low. At a market capitalisation of Rs 6,389 Cr, it is tracked as part of the Pharmaceuticals sector on Univest.

Is Senores Pharmaceuticals the Best Stock in Its Sector?

Senores Pharmaceuticals makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 12.36% ROE with a 48.83x P/E against the sector’s 37.19x Industry P/E. Senores Pharmaceuticals’ 48.83x P/E is well above the 37.19x Industry P/E, and with a 12.36% ROE and a 6.84x price to book after the stock doubled from its 52-week low, the market is already pricing in strong growth.

Metric	Senores Pharmaceuticals
CMP (NSE)	Rs 1,401.30
52-Week High / Low	Rs 1,599.00 / Rs 700.75
Market Cap	Rs 6,389 Cr
P/E (TTM) vs Industry P/E	48.83x vs 37.19x
P/B	6.84
ROE	12.36%
EPS (TTM)	Rs 28.41
Dividend Yield	0.00%
Debt to Equity	0.37

Compare Senores Pharmaceuticals Against Other Pharmaceuticals Sector Stocks

How Senores Pharmaceuticals Compares Against Its Pharmaceuticals Sector Peers

The table below sets Senores Pharmaceuticals against 2 other Pharmaceuticals sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Senores Pharmaceuticals	6,389	48.83	12.36%	0.37
Marksans Pharma	14,698	28.20	13.82%	0.11
Caplin Point Laboratories	20,365	30.04	17.88%	0.00
Peer average (2 companies)	–	29.12	15.85%	0.06

Against this peer set, Senores Pharmaceuticals’s 12.36% ROE is below the 15.85% peer average, and its P/E of 48.83x runs above the peer average of 29.12x. Senores Pharmaceuticals’ 48.83x P/E is well above the 37.19x Industry P/E, and with a 12.36% ROE and a 6.84x price to book after the stock doubled from its 52-week low, the market is already pricing in strong growth.

What Makes Senores Pharmaceuticals Worth Watching in Pharmaceuticals

• Solid ROE, moderate leverage: A 12.36% ROE alongside a debt to equity ratio of 0.37 is a healthy combination for a growing drug maker.
• Premium to Industry P/E: A 48.83x P/E against a 37.19x Industry P/E is a clear premium.
• Rally to near the high: The stock has doubled from its 52-week low and sits close to its high, so expectations are already elevated.

Senores Pharmaceuticals Valuation: Is It Justified?

Senores Pharmaceuticals’ 48.83x P/E is well above the 37.19x Industry P/E, and with a 12.36% ROE and a 6.84x price to book after the stock doubled from its 52-week low, the market is already pricing in strong growth. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Sarveshwar Foods the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Senores Pharmaceuticals and other Pharmaceuticals sector stocks.

How to Track Senores Pharmaceuticals Before You Invest

Before deciding whether Senores Pharmaceuticals deserves its label as the best stock in its sector for your own portfolio, compare it directly against Pharmaceuticals sector peers using the steps below.

1. Open the Univest Screener and search for Senores Pharmaceuticals to view live price, valuation ratios, and peer comparisons within the Pharmaceuticals sector.
2. Compare its P/E, P/B, and ROE against other Pharmaceuticals sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Senores Pharmaceuticals earns a place in the best stock in its sector conversation on the strength of a 12.36% ROE and a P/E of 48.83x against a 37.19x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Senores Pharmaceuticals the best stock in its sector?

Ans. Senores Pharmaceuticals has a 12.36% ROE and trades at 48.83x P/E against a 37.19x Industry P/E, and compares below the peer average ROE of 15.85% in this article’s named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Senores Pharmaceuticals?

Ans. Senores Pharmaceuticals was trading at Rs 1,401.30 on the NSE as of 07 October 2026, within its 52-week range of Rs 700.75 to Rs 1,599.00.

What sector does Senores Pharmaceuticals belong to?

Ans. Senores Pharmaceuticals is classified under the Pharmaceuticals sector on Univest.

How does Senores Pharmaceuticals compare to its sector peers on P/E?

Ans. Senores Pharmaceuticals’s P/E of 48.83x is above the 29.12x average of the 2 named peers compared in this article.

What is Senores Pharmaceuticals’s return on equity?

Ans. Senores Pharmaceuticals reported a return on equity of 12.36%, which is below the 15.85% average of its named peers in this comparison.

Should I invest in Senores Pharmaceuticals based on its sector position?

Ans. Senores Pharmaceuticals’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.

{“@context”: “https://schema.org”, “@type”: “FAQPage”, “mainEntity”: [{“@type”: “Question”, “name”: “Is Senores Pharmaceuticals the best stock in its sector?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Senores Pharmaceuticals has a 12.36% ROE and trades at 48.83x P/E against a 37.19x Industry P/E, and compares below the peer average ROE of 15.85% in this article’s named comparison, so the answer depends on what an investor is prioritising.”}}, {“@type”: “Question”, “name”: “What is the current share price of Senores Pharmaceuticals?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Senores Pharmaceuticals was trading at Rs 1,401.30 on the NSE as of 07 October 2026, within its 52-week range of Rs 700.75 to Rs 1,599.00.”}}, {“@type”: “Question”, “name”: “What sector does Senores Pharmaceuticals belong to?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Senores Pharmaceuticals is classified under the Pharmaceuticals sector on Univest.”}}, {“@type”: “Question”, “name”: “How does Senores Pharmaceuticals compare to its sector peers on P/E?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Senores Pharmaceuticals’s P/E of 48.83x is above the 29.12x average of the 2 named peers compared in this article.”}}, {“@type”: “Question”, “name”: “What is Senores Pharmaceuticals’s return on equity?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Senores Pharmaceuticals reported a return on equity of 12.36%, which is below the 15.85% average of its named peers in this comparison.”}}, {“@type”: “Question”, “name”: “Should I invest in Senores Pharmaceuticals based on its sector position?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Senores Pharmaceuticals’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.”}}]}